{"filing":{"accession_number":"0001193125-26-265852","cik":"0001395937","ticker":"SNDX","company_name":"Syndax Pharmaceuticals Inc","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"sndx-20260610.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526265852/sndx-20260610.htm"},"events":[{"id":5657,"run_id":4959,"accession_number":"0001193125-26-265852","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Syndax Pharmaceuticals held its Annual Meeting of Stockholders on June 10, 2026, with shareholders voting on five proposals: election of directors (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, and approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan. All proposals passed.","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5862,"accession_number":"0001193125-26-265852","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval and implementation of two new equity compensation plans: the 2026 Equity Incentive Plan (reserving 7.2 million shares for grants of options, RSUs, and performance awards to employees, directors, and consultants) and the 2026 Employee Stock Purchase Plan. These are compensatory arrangements for officers and employees, filed under Item 5.02(e), and represent material changes to the Company's equity compensation framework following expiration of the 2015 plans.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:20.387230+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5863,"accession_number":"0001193125-26-265852","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Syndax Pharmaceuticals' Annual Meeting held on June 10, 2026, filed under Item 5.07. The section reports voting outcomes for five proposals: director elections (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, approval of the 2026 Plan, and approval of the 2026 ESPP, with detailed vote tallies for each. All proposals passed, making this a material disclosure of shareholder actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:20.387230+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5862,"accession_number":"0001193125-26-265852","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval and implementation of two new equity compensation plans: the 2026 Equity Incentive Plan (reserving 7.2 million shares for grants of options, RSUs, and performance awards to employees, directors, and consultants) and the 2026 Employee Stock Purchase Plan. These are compensatory arrangements for officers and employees, filed under Item 5.02(e), and represent material changes to the Company's equity compensation framework following expiration of the 2015 plans.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:20.387230+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-10"},{"id":5863,"accession_number":"0001193125-26-265852","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Syndax Pharmaceuticals' Annual Meeting held on June 10, 2026, filed under Item 5.07. The section reports voting outcomes for five proposals: director elections (Legault and Metzger), advisory vote on executive compensation, ratification of auditors, approval of the 2026 Plan, and approval of the 2026 ESPP, with detailed vote tallies for each. All proposals passed, making this a material disclosure of shareholder actions.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:20.387230+00:00","company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","filing_date":"2026-06-10"}]}